New drug cocktail targets rare blood cancer in promising trial
NCT ID NCT04216524
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment plan for people with a rare and aggressive blood cancer called BPDCN. The plan combines two targeted drugs (tagraxofusp and venetoclax) with standard chemotherapy to kill cancer cells. The goal is to see if this combination can control the disease longer and help more patients achieve remission. About 40 adults with newly diagnosed or returning BPDCN will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Selective immune cell removal may tame transplant complications
- New drug combo may make cord blood transplants safer for blood cancer patients
- Blood cancer transplant study tests safer GVHD prevention
- Experimental drug targets rare blood cancer in tiny trial
- New cord blood transplant method aims to beat high-risk blood cancers
- Liver study for cancer drug stopped early – only 2 people joined